14 results on '"Jouneau, Stéphane"'
Search Results
2. To be malnourished or not to be malnourished: that is the question!
- Author
-
Jouneau, Stéphane, primary, Kerjouan, Mallorie, additional, and Thibault, Ronan, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation
- Author
-
Justet, Aurélien, primary, Klay, Dymph, additional, Porcher, Raphaël, additional, Cottin, Vincent, additional, Ahmad, Kais, additional, Molina Molina, Maria, additional, Nunes, Hilario, additional, Reynaud-Gaubert, Martine, additional, Naccache, Jean Marc, additional, Manali, Effrosyni, additional, Froidure, Antoine, additional, Jouneau, Stéphane, additional, Wemeau, Lidwine, additional, Andrejak, Claire, additional, Gondouin, Anne, additional, Hirschi, Sandrine, additional, Blanchard, Elodie, additional, Bondue, Benjamin, additional, Bonniaud, Philippe, additional, Tromeur, Cécile, additional, Prévot, Grégoire, additional, Marchand-Adam, Sylvain, additional, Funke-Chambour, Manuela, additional, Gamez, Anne Sophie, additional, Ba, Ibrahima, additional, Papiris, Spyridon, additional, Grutters, Jan, additional, Crestani, Bruno, additional, van Moorsel, Coline, additional, Kannengiesser, Caroline, additional, and Borie, Raphaël, additional
- Published
- 2020
- Full Text
- View/download PDF
4. High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU
- Author
-
Guy, Tiphaine, primary, Créac'hcadec, Audrey, additional, Ricordel, Charles, additional, Salé, Alexandre, additional, Arnouat, Baptiste, additional, Bizec, Jean-Louis, additional, Langelot, Marie, additional, Lineau, Christine, additional, Marquette, David, additional, Martin, Françoise, additional, Lederlin, Mathieu, additional, and Jouneau, Stéphane, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!
- Author
-
Jouneau, Stéphane, primary, Lederlin, Mathieu, additional, Vernhet, Laurent, additional, and Thibault, Ronan, additional
- Published
- 2019
- Full Text
- View/download PDF
6. Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS
- Author
-
Grégoire, Murielle, primary, Uhel, Fabrice, additional, Lesouhaitier, Mathieu, additional, Gacouin, Arnaud, additional, Guirriec, Marion, additional, Mourcin, Frederic, additional, Dumontet, Erwan, additional, Chalin, Arnaud, additional, Samson, Michel, additional, Berthelot, Laure-Line, additional, Tissot, Adrien, additional, Kerjouan, Mallorie, additional, Jouneau, Stéphane, additional, Le Tulzo, Yves, additional, Tarte, Karin, additional, Zmijewski, Jaroslaw W., additional, and Tadié, Jean-Marc, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis
- Author
-
Jouneau, Stéphane, primary, Ballerie, Alice, additional, Kerjouan, Mallorie, additional, Demant, Xavier, additional, Blanchard, Elodie, additional, and Lederlin, Mathieu, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency
- Author
-
Ballerie, Alice, primary, Nimubona, Stanislas, additional, Meunier, Catherine, additional, Gutierrez, Francisco Llamas, additional, Desrues, Benoît, additional, Delaval, Philippe, additional, and Jouneau, Stéphane, additional
- Published
- 2016
- Full Text
- View/download PDF
9. Prevalence and risk factors for COPD in farmers: a cross-sectional controlled study
- Author
-
Guillien, Alicia, primary, Puyraveau, Marc, additional, Soumagne, Thibaud, additional, Guillot, Stéphanie, additional, Rannou, Fabrice, additional, Marquette, David, additional, Berger, Patrick, additional, Jouneau, Stéphane, additional, Monnet, Elisabeth, additional, Mauny, Frédéric, additional, Laplante, Jean-Jacques, additional, Dalphin, Jean-Charles, additional, and Degano, Bruno, additional
- Published
- 2015
- Full Text
- View/download PDF
10. Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial.
- Author
-
Mansy L, Caille A, Reynaud-Gaubert M, Bermudez J, Bonniaud P, Borie R, Brillet PY, Cadranel J, Court-Fortune I, Crestani B, Debray MP, Duprez M, Guillaumot A, Hirschi-Santelmo S, Israel-Biet D, Jouneau S, Juvin K, Kerjouan M, Mankikian J, Marquette CH, Naccache JM, Nunes H, Plantier L, Prevot G, Quetant S, Traclet J, Valentin V, Uzunhan Y, Wémeau-Stervinou L, Cottin V, and Marchand-Adam S
- Subjects
- Humans, Female, Follow-Up Studies, Male, Middle Aged, Treatment Outcome, Aged, Immunosuppressive Agents therapeutic use, Mycophenolic Acid therapeutic use, Lung Diseases, Interstitial drug therapy, Rituximab therapeutic use
- Abstract
Competing Interests: Conflict of interest: R. Borie has received over the past 3 years, outside the submitted work, grants or contracts from Boehringer Ingelheim, consulting fees from Boehringer Ingelheim, Sanofi and Ferrer, payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim and Sanofi, and support for attending meetings and/or travel from Boehringer Ingelheim. P. Bonniaud has received over the past 3 years, outside the submitted work, a research grant from AstraZeneca, payment or honoraria for symposia from Sanofi and AstraZeneca, support for attending medical and research meetings from AstraZeneca, Novartis, Sanofi, Boehringer and Stallergene, and personal fees for advisory boards from AstraZeneca, Novartis, Sanofi, GlaxoSmithKline and Boehringer. B. Crestani has received over the past 3 years, outside the submitted work, grants or contracts from Boehringer Ingelheim, consulting fees, payments or honoraria for lectures, presentations, manuscript writing or educational events, support for attending meetings and/or travel from AstraZeneca, BMS, Boehringer Ingelheim, GSK, Novartis, Roche, Sanofi and Chiesi; he has participated in data safety monitoring board or advisory board for BMS, Boehringer Ingelheim, Horizon and Sanofi, and is the president of the board of trustees of the Fondation du Souffle (a French charity). M-P. Debray has received over the past 3 years, outside the submitted work, payments or honoraria for lectures, presentations, manuscript writing or educational events, support for attending meetings and/or travel from Boehringer Ingelheim, GSK and Sanofi. D. Israel-Biet has received over the past 3 years, outside the submitted work, consulting fees and support for attending meetings and/or travel from Boehringer Ingelheim. V. Cottin has received over the past 3 years, outside the submitted work, an unrestricted grant (paid to institution) from Boehringer Ingelheim, consulting fees, payments or honoraria for lectures, presentations, manuscript writing or educational events, support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, BMS/Celgene, CSL (Behring, Vifor), Ferrer/United Therapeutics, GSK, Pliant, PureTech, RedX, Roche, Sanofi, Shionogi and Vifor; he has participated in data safety monitoring boards for Galapagos, Galecto, GSK and Molecure, and has been in an adjudication committee for Fibrogen. S. Quetant has received over the past 3 years, outside the submitted work, support for attending meetings and personal fees for advisory board work from Boehringer Ingelheim. A. Guillaumot has received over the past 3 years, outside the submitted work, honoraria for presentations from Boehringer Ingelheim and support for attending meetings and/or travel from Boehringer Ingelheim, CSL Behring and GSK. S. Hirschi-Santelmo has received over the past 3 years, outside the submitted work, grants or contracts from l'Agence de la biomédecine, honoraria for presentations or expertise from Boehringer Ingelheim, and support for attending meetings and/or travel from CSL Behring and Boehringer Ingelheim. P-Y. Brillet has received over the past 3 years, outside the submitted work, honoraria for lectures from Boehringer Ingelheim and Sanofi, and support for attending a national meeting from Boehringer Ingelheim. S. Marchand-Adam has received over the past 3 years, outside the submitted work, an unrestricted grant (paid to institution) from Boehringer Ingelheim, consulting fees from AstraZeneca and Boehringer Ingelheim, and support for attending meetings from Boehringer Ingelheim. V. Valentin, has received over the past 3 years, outside the submitted work, support for attending meetings and/or travel from Boehringer Ingelheim. Y. Uzunhan has received over the past 3 years, outside the submitted work, grants or contracts from Oxyvie, consulting fees from Boehringer Ingelheim and Pfizer, payments or honoraria for lectures, presentations, manuscript writing or educational events from Sanofi, Boehringer Ingelheim and CSL Vifor, support for attending meetings and/or travel from Oxyvie and Boehringer Ingelheim, and has participated in data safety monitoring boards or advisory boards for Boehringer Ingelheim. The remaining authors have no potential conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
11. To be malnourished or not to be malnourished: that is the question!
- Author
-
Jouneau S, Kerjouan M, and Thibault R
- Subjects
- Humans, Body Weight
- Abstract
Competing Interests: Conflict of interest: S. Jouneau reports fees, funding, or reimbursement for national and international conferences, boards, expert or opinion groups, and research projects over the past 5 years from Actelion, AIRB, AstraZeneca, Bellerophon Therapeutics, Biogen, BMS, Boehringer Ingelheim, Chiesi, FibroGen, Galecto Biotech, Genzyme, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pharm-Olam, Pfizer, Pliant Therapeutics, F. Hoffmann-La Roche, Ltd, Sanofi and Savara-Serendex, outside the submitted work. Conflict of interest: M. Kerjouan has nothing to disclose. Conflict of interest: R. Thibault has received royalties for designing the Simple Evaluation of Food Intake (SEFI) (Knoë, le Kremlin Bicêtre, France) tool, and consulting fees from F. Hoffmann-La Roche, Ltd.
- Published
- 2022
- Full Text
- View/download PDF
12. Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation.
- Author
-
Justet A, Klay D, Porcher R, Cottin V, Ahmad K, Molina Molina M, Nunes H, Reynaud-Gaubert M, Naccache JM, Manali E, Froidure A, Jouneau S, Wemeau L, Andrejak C, Gondouin A, Hirschi S, Blanchard E, Bondue B, Bonniaud P, Tromeur C, Prévot G, Marchand-Adam S, Funke-Chambour M, Gamez AS, Ba I, Papiris S, Grutters J, Crestani B, van Moorsel C, Kannengiesser C, and Borie R
- Subjects
- Humans, Indoles, Mutation, Pyridones therapeutic use, Treatment Outcome, Idiopathic Pulmonary Fibrosis drug therapy, Idiopathic Pulmonary Fibrosis genetics, Telomere
- Abstract
Competing Interests: Conflict of interest: A. Justet reports grants from Roche, personal fees from Boeringher Ingelheim, outside the submitted work. Conflict of interest: D. Klay has nothing to disclose. Conflict of interest: R. Porcher has nothing to disclose. Conflict of interest: V. Cottin reports personal fees for advisory board work and lectures, and non-financial support for meeting attendance from Actelion, grants, personal fees for consultancy and lectures, and non-financial support for meeting attendance from Boehringer Ingelheim, personal fees for advisory board and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for advisory board work and lectures from Novartis, personal fees for consultancy, lectures, steering committee and data monitoring committee work, and non-financial support for meeting attendance from Roche/Promedior, personal fees for lectures from Sanofi and AstraZeneca, personal fees for data monitoring committee work from Celgene and Galecto, personal fees for advisory board work from Shionogi, outside the submitted work. Conflict of interest: K. Ahmad reports personal fees from Roche and Boeringher Ingelheim, outside the submitted work. Conflict of interest: M. Molina-Molina reports grants and personal fees from Roche, Boehringer Ingelheim and Esteve-Teijin, personal fees from Chiesi, Pfizer and Galapagos, outside the submitted work. Conflict of interest: H. Nunes reports personal fees from Intermune, Roche, Boehringer Ingelheim and Sanofi, outside the submitted work. Conflict of interest: M. Reynaud-Gaubert has nothing to disclose. Conflict of interest: J.M. Naccache has nothing to disclose. Conflict of interest: E. Manali reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study. Conflict of interest: A. Froidure reports grants, personal fees and non-financial support from Roche and Boehringer Ingelheim, personal fees and non-financial support from AstraZeneca, personal fees from GlaxoSmithKline, outside the submitted work. Conflict of interest: S. Jouneau reports fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups, research projects over the past 3 years from AIRB, Bellorophon Therapeutics, Biogen, Boehringer, Chiesi, Fibrogen, Galecto Biotech, Genzyme, Gilead, LVL, Novartis, Olam Pharm, Pfizer, Pliant Therapeutics, Roche, Sanofi and Savara-Serendex. Conflict of interest: L. Wemeau has nothing to disclose. Conflict of interest: C. Andrejak has nothing to disclose. Conflict of interest: A. Gondouin has nothing to disclose. Conflict of interest: S. Hirschi has nothing to disclose. Conflict of interest: E. Blanchard has nothing to disclose. Conflict of interest: B. Bondue reports grants and personal fees from Boeringher Ingleheim and Hoffman La Roche, outside the submitted work. Conflict of interest: P. Bonniaud reports personal fees from Roche, Novartis, Boeringher, TEVA and AstraZeneca, outside the submitted work. Conflict of interest: C. Tromeur has nothing to disclose. Conflict of interest: G. Prevot reports personal fees from Actelion, Bayer, Boehringer Ingelheim and Roche, outside the submitted work. Conflict of interest: S. Marchand-Adam has nothing to disclose. Conflict of interest: M. Funke-Chambour reports grants from Roche and Boehringer Ingelheim, during the conduct of the study. Conflict of interest: A.S. Gamez has nothing to disclose. Conflict of interest: I. Ba has nothing to disclose. Conflict of interest: S. Papiris reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study. Conflict of interest: J. Grutters has nothing to disclose. Conflict of interest: B. Crestani reports personal fees from AstraZeneca and Sanofi, grants and personal fees from Boeringher Ingelheim and Roche, personal fees and non-financial support from BMS, outside the submitted work. Conflict of interest: C. van Moorsel has nothing to disclose. Conflict of interest: C. Kannengiesser has nothing to disclose. Conflict of interest: R. Borie reports grants and personal fees from Boeringher Ingelheim and Roche, personal fees from Savapharma, outside the submitted work.
- Published
- 2021
- Full Text
- View/download PDF
13. Prevalence and risk factors for COPD in farmers: a cross-sectional controlled study.
- Author
-
Guillien A, Puyraveau M, Soumagne T, Guillot S, Rannou F, Marquette D, Berger P, Jouneau S, Monnet E, Mauny F, Laplante JJ, Dalphin JC, and Degano B
- Subjects
- Adult, Aged, Agricultural Workers' Diseases physiopathology, Animals, Case-Control Studies, Cattle, Cross-Sectional Studies, Female, Forced Expiratory Volume, France epidemiology, Humans, Male, Middle Aged, Poultry, Prevalence, Pulmonary Disease, Chronic Obstructive physiopathology, Risk Factors, Swine, Vital Capacity, Agricultural Workers' Diseases epidemiology, Animal Husbandry statistics & numerical data, Crop Production statistics & numerical data, Farmers statistics & numerical data, Occupational Exposure statistics & numerical data, Pulmonary Disease, Chronic Obstructive epidemiology, Smoking epidemiology
- Abstract
There are conflicting data regarding the magnitude and determinants of chronic obstructive pulmonary disease (COPD) risk in farmers.In a cross-sectional study of 917 nonfarming working controls and 3787 farmers aged 40-75 years, we assessed respiratory symptoms, tobacco exposure, job history (without direct exposure measurement) and lung function. COPD was defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion (post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.70) and by the Quanjer reference equation (post-bronchodilator FEV1/FVC
- Published
- 2016
- Full Text
- View/download PDF
14. Ambulatory management of large primary spontaneous pneumothorax.
- Author
-
Jouneau S, Sohier L, and Desrues B
- Subjects
- Female, Humans, Male, Drainage methods, Pneumothorax therapy
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.